Introduction {#s1}
============

Many familial and population based studies have demonstrated the role of genetic factors in susceptibility to multiple sclerosis (MS). By far the most important and consistently replicated genetic risk factor associated with MS is the HLA- DRB1\*1501-DQB1\*0602 (HLA-DR15) haplotype [@pone.0010003-The1] which carries an odds ratio of between 2.0 and 3.5 for MS [@pone.0010003-Masterman1].

In the last two years, a series of genome-wide association studies have identified other SNPs that are associated with multiple sclerosis. Some of the recent discoveries are polymorphisms in genes for interleukin 2 receptor alpha (*IL2RA*), interleukin 7 receptor (*IL7R*), C-type lectin, family 16, member A (*CLEC16A*), ribosomal protein L5 (*RPL5*)/*EV15* locus, *CD40*, and rs703842 on chromosome 12 [@pone.0010003-The1], [@pone.0010003-Zhang1], [@pone.0010003-Rubio1], [@pone.0010003-ANZgene1], [@pone.0010003-Stankovich1]. Individually, these SNPs contribute a small proportion to overall MS risk, with allelic odds ratios of between 1.1--1.3 [@pone.0010003-The1], [@pone.0010003-Zhang1], [@pone.0010003-Rubio1], [@pone.0010003-ANZgene1], [@pone.0010003-Stankovich1].

As well as influencing MS risk, the HLA-DR15 haplotype has been reported to reduce the age of MS onset in MS patients in a number of large, independent studies from Scandinavia and Britain [@pone.0010003-Masterman1], [@pone.0010003-Smestad1], [@pone.0010003-Hensiek1], [@pone.0010003-Weatherby1], [@pone.0010003-Celius1] although this was not replicated in a large US study [@pone.0010003-Barcellos1]. Interestingly, in one of these studies [@pone.0010003-Masterman1], the HLA-DR15 allele was significantly more frequent in patients with definite MS than in patients with possible or probable MS (defined according to the Poser criteria) which may be a proxy for severity. In another study HLA-DR2 (which includes the HLA-DR15 risk allele), was associated with increased risk of a more severe course of disease [@pone.0010003-Barcellos2]. In addition HLA-DR15 positivity has been associated with increased lesion load at MS onset [@pone.0010003-Hauser1]. At the most benign end of the wide phenotypic MS spectrum, it may be an entirely subclinical disease, exemplified in twin studies, in which 13% percent of asymptomatic monozygotic twins and 9% of asymptomatic dizygotic twins of MS index cases exhibited cerebral MRI lesions typical of MS [@pone.0010003-Thorpe1]. It is therefore possible that MS susceptibility alleles actually represent determinants of severity, acting at the mildest end of the MS spectrum, by increasing the likelihood of clinically overt disease and thus, diagnosis. If this were the case, and if genetic modulation of MS severity were present across the clinical spectrum of disease, one might also be able to detect an influence of risk SNPs on MS phenotype, manifesting as an increased disease severity in MS patients carrying the risk SNPs.

In order to test this hypothesis, we have chosen to examine the potential contribution of the susceptibility SNPs in *IL2RA*, *IL7R*, *CLEC16A*, *RPL5*, *CD40*, *CD58* and the Chr12 loci to MS severity, using a well-defined cohort of 1006 patients with relapsing-remitting and secondary progressive MS from Australia. MS clinical outcome measures used in this study included age of onset, time interval from the first demyelinating event (FDE) to first relapse, and MS Severity Score (MSSS). Cerebral atrophy was assessed using a validated linear cerebral MRI measure, the intercaudate ratio (ICR), for 755 patients. In addition, cognitive testing using the symbol digit modalities test (SDT) was available for 869 patients.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

The ethics committees involved were the Melbourne Health Human Research and Ethics Committee (HREC) (lead committee), Eastern Health HREC, Box Hill, Austin and Repatriation Hospitals HREC, Heidelberg, Barwon Health HREC, Geelong, St Vincent\'s Hospital HREC, Fitzroy, Ballarat Base Hospital HREC, Ballarat, Gippsland Base Hospital HREC, Sale (all in Victoria), Albury Base Hospital HREC, Albury, (NSW) and the Tasmania Health and Medical HREC (Tasmania). The ethics committees approved the project and signed informed consent was obtained from all participants.

A total of 1006 patients with relapsing-remitting (RRMS) and secondary progressive MS (SPMS) were recruited from Victorian and Tasmania in South-Eastern Australia between 2002 and 2004 [@pone.0010003-Rubio1], [@pone.0010003-Perera1], [@pone.0010003-vanderWalt1].

All of the patients were assessed by six MS specialist neurologists. Clinical information including the age of onset, sex, time interval between first demyelinating event and first relapse, number of relapses and disease course of patients was collected. Disability in patients was determined using the Kurtzke Expanded Disability Status Scale (EDSS) The EDSS is a 10-point disease severity score with half-point increments which itself is derived from 9 ratings for individual neurological domains, including visual, brainstem, motor, sensory, cerebellar, bladder/bowel and cognitive function, and walking distance [@pone.0010003-Kurtzke1]. The EDSS was used in combination with disease duration to calculate the MS Severity Score (MSSS) with reference to the global MSSS table. The MSSS table essentially ranks individuals from lowest EDSS to highest EDSS for a given disease duration, and expresses this as a decile rank between 0 (least affected) and 10 (most severely affected) [@pone.0010003-Roxburgh1]. Cognitive disability was also assessed in 869 patients using the symbol digit modalities test (SDT) of the Wechsler Adult Intelligence Scale-revised [@pone.0010003-Wechsler1]. SDT scores were adjusted for disease duration.

Age of onset was defined as the age at which the patient experienced their first demyelinating event and the interval between first demyelinating event and first relapse was determined from patient recall facilitated by a detailed questionnaire (provided to participants prior to the clinical assessment) and confirmed by medical notes (obtained wherever possible from their treating physician). Based on the country of birth of the participant\'s grand parents, the subjects were predominantly of Northern European ancestry, the majority were of Anglo Celtic (73%) or Southern European descent (16%). The remainder were of Western European (5%), Eastern European (4%), Scandinavian (1%) or other (1%) descent.

Genotyping {#s2b}
----------

DNA was collected and extracted from blood samples using either the Nucleon Genomic DNA Extraction Kit (GE Lifescience) or phenol-chloroform extraction. The majority of SNPs were genotyped at the Broad Institute for Genotyping and Analysis (<http://www.broad.mit.edu/gen_analysis/genotyping/>) with Sequenom\'s MassARRAY platform (San Diego, CA, USA) using the iPlex SNP assay design system [@pone.0010003-Rubio1]. However the SNPs rs6074022 and rs703842 were genotyped or imputed in a subset of 898 RRMS and SPMS patients as part of a genome-wide association study [@pone.0010003-ANZgene1], either in the GWAS phase (Illumina 370CNV arrays, n = 581) or in the replication phase (Sequenom MassARRAY platform, n = 317). Presence or absence of the HLA-DR15 allele was determined from HLA-DRB1 typing performed previously in 954 of the cases using sequence-specific oligonucleotide hybridization and nucleotide sequencing [@pone.0010003-Stankovich1].

MRI assessment {#s2c}
--------------

Existing MRI scans were retrieved for measurements of linear markers of brain atrophy. Scans were available for 755 of the patients.

The clinical scans were performed at multiple centres and a variety of protocols were used, but generally the T1-weighted axial scans were of 5mm thickness with either no gaps (inter-leaved) or 2.5mm gaps. Intercaudate distance (ICD) was described as the minimum distance between the medial borders of the head of the caudate nuclei as previously described and validated [@pone.0010003-Butzkueven1]. The intercaudate ratio (ICR) was calculated as a fraction of the ICD to the transverse skull diameter (TSD) where the TSD was defined as the minimum distance separating the inner borders of the skull at the level of the most rostral part of the frontal horns. ICD and TSD were obtained from the same MRI slice, specifically the most caudal axial T1-weighted slice on which the frontal horns were at maximal width. ICR was log-transformed to give a more normally-distributed phenotype, and adjusted for the disease duration.

Statistical Analysis {#s2d}
--------------------

Five measurements of disease severity (MSSS, age of onset, time between the FDE and first relapse, duration-adjusted SDT and duration-adjusted log(ICR)) were tested for association with SNPs in *CLEC16A* (rs6498169), *IL2RA* (rs2104286), *IL7R* (rs6897932), *CD58* (rs12044852), *RPL5* (rs6604026), *CD40* (rs6074022) genes and at Chr12q13--14 (rs703842). Statistical analysis was performed using Stata 10 statistical software (StataCorp). Testing was performed by regression of continuous severity variables on the number of minor alleles carried by patients. All traits were approximately normally distributed except for MSSS (uniformly distributed by definition). For nominal genotype-phenotype associations (p\<0.05), further analyses were performed, stratifying by sex and presence or absence of HLA-DR15. In addition, mean values and 95% confidence intervals were calculated for each severity variable, stratified by genotype. For variables associated with disease duration (ICR and SDT), means and confidence intervals were standardized to the mean disease duration (13.4 years) using the Stata 'lincom' command. The statistical methodology used in this paper has been previously published [@pone.0010003-vanderWalt1].

Results {#s3}
=======

There were 1006 patients in total, of whom 78% were female. Patient demographic information is displayed in [Table 1](#pone-0010003-t001){ref-type="table"}. Approximately 57% of patients carried at least one copy of HLA-DR15. Mean values of each of the MS severity variables were similar in each of the categories of females and males, and DR15-positive and DR15-negative individuals with the exception of age of onset, which was lower in DR15-positive patients, as expected in a cohort of northern European origin [@pone.0010003-VanderWalt1]. The ranges for each variable were; MSSS 0.05--9.82, Age of onset 7-65yrs, time between first demyelinating event (FDE) and first relapse 0--52 yrs, SDT 0--80, log(ICR) −1.099 to −2.996, means and standard deviations for these variables are shown in [Table 1](#pone-0010003-t001){ref-type="table"}. [Table 2](#pone-0010003-t002){ref-type="table"} shows means and 95% confidence intervals for each of the severity measures stratified by genotype at each of the tested MS susceptibility SNPs. Due to the continuous nature of sample collection, some individuals were not typed for rs6074022 or rs703842, for which 897 and 898 genotypes were available, respectively, and for other assays, genotyping results were rejected in up to 5% of reactions when SNPs were called ambiguously.

10.1371/journal.pone.0010003.t001

###### Demographic and clinical data for 1006 MS patients with RRMS or SPMS.

![](pone.0010003.t001){#pone-0010003-t001-1}

  Metric                                                                                Total          Females          Males         HLA-DR15-       HLA-DR15+
  -------------------------------------------------------------------------------- --------------- --------------- --------------- --------------- ---------------
  Patients                                                                              1006             781             225             414             540
  Age of onset                                                                      31.20 (9.84)    31.15 (9.74)    31.36 (10.19)   32.08 (10.18)   30.46 (9.56)
  Time between FDE and 1^st^ relapse (N = 1002)[\*](#nt102){ref-type="table-fn"}     5.13 (6.53)     5.01 (6.22)     5.56 (7.51)     5.25 (6.31)     5.03 (6.29)
  MSSS                                                                               4.12 (2.62)     3.96 (2.54)     4.70 (2.79)     4.10 (2.58)     4.20 (2.63)
  Symbol Digit Test (N = 850)                                                       41.44 (12.69)   43.09 (12.26)   35.51 (12.49)   41.43 (12.32)   41.21 (13.06)
  Log (ICD/TCD) ratio (N = 755)                                                     −2.08 (0.30)    −2.11 (0.30)    −1.99 (0.26)    −2.08 (0.28)    −2.08 (0.31)

All results shown as: Mean (standard deviation).

\*FDE = first demyelinating event.

HLA-DR15 status was available for 954 patients.

10.1371/journal.pone.0010003.t002

###### MS disease severity metrics stratified by genotype.

![](pone.0010003.t002){#pone-0010003-t002-2}

                                             MSSS    Age of onset   Time 1&2   SDT (at mean duration)   Log((ICR) (at mean duration)                                                                                  
  -------------- ------------ --- --- ----- ------- -------------- ---------- ------------------------ ------------------------------ -------- ------- -------- -------- -------- -------- -------- -------- -------- --------
  CLEC16A         rs6498169    G   0   355   4.147      3.880        4.413             31.242                      30.231              32.253   4.957   4.300    5.615    41.903   40.564   43.242   −2.092   −2.126   −2.058
                                   1   489   4.120      3.882        4.358             31.012                      30.120              31.905   5.281   4.682    5.880    40.753   39.640   41.867   −2.060   −2.089   −2.030
                                   2   112   4.156      3.677        4.634             32.152                      30.335              33.968   4.866   3.678    6.054    42.473   40.243   44.702   −2.096   −2.156   −2.036
  IL2RA           rs2104286    G   0   563   4.160      3.938        4.382             31.020                      30.187              31.852   5.062   4.530    5.595    41.315   40.266   42.363   −2.072   −2.099   −2.045
                                   1   378   4.008      3.749        4.268             31.603                      30.623              32.584   5.221   4.578    5.863    41.749   40.481   43.016   −2.090   −2.123   −2.056
                                   2   38    4.810      3.975        5.644             29.474                      26.408              32.540   7.053   3.693    10.412   40.137   36.340   43.934   −2.041   −2.145   −1.937
  IL7R            rs6897932    T   0   542   4.105      3.887        4.324             31.059                      30.200              31.918   5.293   4.746    5.839    41.259   40.213   42.305   −2.077   −2.105   −2.049
                                   1   356   4.190      3.914        4.466             31.225                      30.247              32.202   4.992   4.279    5.704    41.270   39.939   42.600   −2.072   −2.106   −2.038
                                   2   57    4.024      3.313        4.736             32.825                      30.181              35.468   4.246   2.939    5.553    43.752   40.238   47.267   −2.089   −2.177   −2.000
  CD58            rs12044852   A   0    6    3.932      0.873        6.990             33.167                      21.856              44.478   5.833   −0.301   11.968   44.557   34.363   54.752   −1.943   −2.223   −1.663
                                   1   194   4.040      3.671        4.409             30.727                      29.242              32.212   5.440   4.528    6.353    41.421   39.658   43.184   −2.100   −2.146   −2.053
                                   2   758   4.168      3.981        4.355             31.302                      30.610              31.995   5.050   4.581    5.520    41.396   40.494   42.297   −2.069   −2.093   −2.045
  EV15/RPL5       rs6604026    C   0   464   4.125      3.885        4.364             31.086                      30.163              32.010   5.577   4.939    6.215    41.926   40.774   43.077   −2.073   −2.103   −2.043
                                   1   419   4.177      3.925        4.429             31.308                      30.386              32.230   4.766   4.176    5.355    40.782   39.571   41.993   −2.068   −2.100   −2.036
                                   2   74    3.938      3.335        4.542             31.527                      29.267              33.787   4.162   2.921    5.403    41.903   39.007   44.799   −2.134   −2.211   −2.057
  CD40            rs6074022    C   0   456   4.005      3.770        4.240             31.167                      30.283              32.050   5.382   4.777    5.988    41.687   40.573   42.801   −2.072   −2.100   −2.044
                                   1   357   4.154      3.881        4.427             30.608                      29.579              31.636   5.425   4.694    6.157    40.543   39.294   41.793   −2.071   −2.104   −2.039
                                   2   84    4.518      3.966        5.071             31.381                      29.212              33.549   4.393   3.144    5.642    37.833   35.242   40.423   −2.068   −2.133   −2.003
  Chr12q 13−14     rs703842    C   0   483   4.002      3.773        4.231             30.911                      30.032              31.790   5.174   4.582    5.767    41.175   40.092   42.258   −2.065   −2.093   −2.037
                                   1   351   4.318      4.047        4.588             31.185                      30.177              32.194   5.493   4.801    6.184    40.112   38.852   41.371   −2.079   −2.110   −2.047
                                   2   64    3.860      3.177        4.543             30.516                      27.953              33.078   5.219   3.305    7.133    42.798   39.775   45.821   −2.071   −2.142   −1.999

Symbol digit test (SDT) and intercaudate ratio (ICR) scores have been standardised to the mean duration of 13.4 years. MSSS is the multiple sclerosis severity score. ICR is the intercaudate distance divided by the transverse skull diameter. Time 1& 2 is the time between the first demyelinating event and first relapse.

The effects of risk SNPS in this cohort of patients was analysed against five MS severity variables, and the results of this analysis are expressed as estimated change in disease severity variable for each additional minor allele ([Table 3](#pone-0010003-t003){ref-type="table"}).

10.1371/journal.pone.0010003.t003

###### Tests of association between SNPs and MS disease severity metrics.

![](pone.0010003.t003){#pone-0010003-t003-3}

                                                        MSSS    Age of onset   Time 1&2    SDT    Log(ICR)                                            
  -------------- ------------ --- ----- ------- ----- -------- -------------- ---------- ------- ---------- ----------- -------- ----------- -------- -------
  CLEC16A         rs6498169    G   A/G   0.371   983   −0.020      0.877        0.207     0.669    −0.029      0.928     −0.228     0.710     0.010    0.536
  IL2RA           rs2104286    G   A/G   0.232   979   0.022       0.879        0.088     0.874    0.465       0.207     0.031      0.964     −0.005   0.775
  IL7R            rs6897932    T   C/T   0.246   955   0.024       0.866        0.515     0.327    −0.410      0.239     0.569      0.409     −0.001   0.951
  CD58            rs12044852   A   C/A   0.108   958   −0.210      0.845        1.982     0.624    0.704       0.793     3.156      0.545     0.111    0.435
  EV15/RPL5       rs6604026    C   T/C   0.296   957   −0.028      0.838        0.221     0.663    −0.754    **0.024**   −0.524     0.422     −0.011   0.507
  CD40            rs6074022    C   T/C   0.293   897   0.215       0.102        −0.148    0.765    −0.289      0.396     −1.529   **0.016**   −0.006   0.716
  Chr12q13--14     rs703842    C   T/C   0.267   898   0.109       0.428        0.022     0.966    0.160       0.654     −0.013     0.985     −0.013   0.444

MAF is the minor allele frequency. Fitted coefficients (coef) give the estimated change in disease severity metric for carriage of each additional minor allele. P-values arise from tests of whether these fitted coefficients differ significantly from zero. Symbol digit test (SDT) and intercaudate ratio (ICR) scores have been adjusted for disease duration. MSSS is the multiple sclerosis severity score. ICR is the intercaudate distance divided by the transverse skull diameter. Time 1& 2 is the time between the first demyelinating event and first relapse.

No associations were found between MS-risk-associated SNPs and MSSS, age of onset, or ICR. We observed a trend towards association between the *RPL5* SNP rs6604026 and the time between FDE and first relapse (p = 0.024), and between the *CD40* SNP rs6074022 and the duration of illness adjusted SDT score (p = 0.016). For both of these associations the minor, disease-associated allele was associated with more severe disease, however these trends were not significant after applying the Bonferroni correction for multiple testing, the threshold for which was p = 0.05/35 = 0.0014.

To account for the possibility that particular subgroups of patients might exhibit different genotype-phenotype effects, we stratified the effect of *RPL5* (rs6604026) genotype on the time between FDE and first relapse, and the effect of *CD40* (rs6074022) genotype on the SDT score by either sex or HLA-DR15 status.

In the subgroup analysis, the effect of *RPL5* (rs6604026) on the time between FDE and first relapse was very similar between groups. There was no significant interaction or trend between rs6604025 and sex (p = 0.915) or between rs6604025 and HLA-DR15 status (p = 0.650) ([Table 4](#pone-0010003-t004){ref-type="table"}). When *CD40* (rs6074022) results were stratified by sex, there was a weak trend towards a stronger effect in males than females (coefficients −3.1247 and −1.1795 respectively), and a weak trend towards a stronger effect in HLA-DR15 negative individuals than HLA-DR15 positive individuals (coefficients −1.8818, and −0.9834 respectively), but these trends were not significant (interaction p-values 0.475 and 0.224, respectively) ([Table 4](#pone-0010003-t004){ref-type="table"}).

10.1371/journal.pone.0010003.t004

###### Nominally significant results (p\<0.05) stratified by sex and DR15 genotype.

![](pone.0010003.t004){#pone-0010003-t004-4}

                           EV15/RPL5   CD40             
  ----------------------- ----------- ------- --------- -------
  Overall                   −0.754     0.024   −1.529    0.016
  female                    −0.765     0.033   −1.1795   0.086
  male                      −0.679     0.412   −3.1247   0.025
  DR15−                     −0.844     0.100   −1.8818   0.054
  DR15+                     −0.540     0.219   −0.9834   0.263
  Interaction with sex       0.086     0.915   0.93613   0.475
  Interaction with DR15      0.304     0.650   −1.7919   0.224

P-values arise from tests of whether these fitted coefficients differ significantly from zero. Time 1& 2 is the time between the first demyelinating event and first relapse. Symbol digit test (SDT) scores have been adjusted for disease duration.

Discussion {#s4}
==========

In this study, we investigated whether seven recently identified MS risk-associated SNPs were acting as modifiers of severity on any of five markers of MS severity in a large cohort of relapsing-remitting and secondary progressive MS patients from south-eastern Australia. We chose to investigate these associations using an additive, allele-load model of inheritance, rather than recessive and dominant models, to reduce multiple testing. We found no evidence that any of the tested SNPs modified the clinical phenotypes of MSSS, age of onset or the time between FDE and first relapse. We also did not detect an effect of the risk SNPs on cerebral atrophy as measured by the ICR, and no evidence of effects on cognitive function as measured by the SDT. We have previously reported that none of the seven risk-associated SNPs tested here are determinants of relapsing versus primary progressive phenotypes [@pone.0010003-ANZgene1]. Similarly, a recent genome-wide association study of 1000 people with MS [@pone.0010003-Baranzini1] investigated SNP markers associated with age of onset, MSSS, cerebral atrophy and T2 lesion load, and none of the seven risk SNPs assessed in this study were reported as showing strong trends of association with the tested phenotypic variations.

In our study, MS risk-associated SNPs in *CD40* and *RPL5* showed weak trends towards association with specific disease severity measures, namely with ICR and time between FDE and first relapse, respectively. These associations were not significant after appropriate correction for multiple testing. As these two SNPs may potentially only be associated with disease severity in subgroups of patients, the subjects were stratified on two known risk factors, sex and HLA-DR15 status. There was weak, non-significant evidence that the *CD40* SNP has a stronger effect on ICD in males and HLA-DR15 negative individuals. The observed lack of effect of *CD40* on phenotype is consistent with a previous study of disease severity (EDSS), which used an extremes of severity approach and could not detect an association between severity and *CD40* genotype [@pone.0010003-Ramagopalan1].

This study only examined associations between the identified risk SNP genotypes and MS disease severity. The currently identified risk SNPs may be causative, or they may be in linkage disequilibrium with as yet unidentified SNPs in the same or neighbouring candidate genes, which could potentially carry stronger associations with MS. Fine mapping or sequencing of genetic regions near the currently identified risk SNPs will probably refine the current MS genetic associations and could also change the results of our analysis of genetic modulation of MS disease severity.

In the analyses utilising the full sample (eg MSSS outcomes), our study had 80% power to detect associations with SNPs that account for at least 1.6% of a trait\'s variance, Due to missing data, power was reduced in some analyses. For the smallest sub-sample (MRI outcomes) we had 80% power to detect associations with SNPs that account for at least 2.1% of variance after correction for the 35 tests in [Table 3](#pone-0010003-t003){ref-type="table"} (significance level of p = 0.0014). We had 80% power to detect nominally significant associations (p = 0.05) with SNPs that account for at least 0.8% of a trait\'s variance (full sample) or at least 1.0% of variance (individuals with MRIs).

Given that our study did not show significant associations between individual risk SNPs and MS severity, we would not expect interactions between multiple SNPs to greatly influence MS severity. However, although the cohort size of this study is large, it still does not permit formal testing of interaction hypotheses, as even interaction tests between any two of the seven risk SNPs would result in 42 interactions to be tested, and the power of such a study would be very low.

Interaction tests between treatment exposures and risk SNPs for association with MS severity are also difficult to conduct because of power issues. However, at the time of clinical assessment, 71% of the study cohort was on treatment with one of four disease-modifying drugs available at the time. If there were a large, SNP-specific treatment effect, we would expect to detect it in this study as the particular SNP would, in this case, be a characteristic of the individuals with reduced MS severity.

Few allelic variations associated with MS severity have been found, and the only one to be confirmed in multiple studies is the association between increasing allele load of HLADR15 and lower age at MS onset [@pone.0010003-Masterman1], [@pone.0010003-Smestad1], [@pone.0010003-Hensiek1], [@pone.0010003-Weatherby1], [@pone.0010003-Celius1]. The effect of HLA-DR15 on other markers of disease severity is contentious. While some studies have shown no effect [@pone.0010003-Zivadinov1], [@pone.0010003-Runmarker1], other studies have shown that HLA-DR15 influences several other markers of MS disease severity including the number of lesions at presentation [@pone.0010003-Hauser1], normalized brain volume, cognitive function [@pone.0010003-Okuda1] and even the type of early clinical manifestation of MS [@pone.0010003-The2]. Of the three alleles of the apoE gene, ApoE4 has been reported to be associated with worse outcome, but large studies, including our own [@pone.0010003-vanderWalt1]and a recent meta-analysis [@pone.0010003-Burwick1] did not confirm any of these effects. Other, as yet unreplicated disease-modifier SNPs have been reported. For example, a SNP in IL-1β, which leads to higher expression of the protein, has been reported to be associated with more benign disease, as assessed by duration-adjusted EDSS [@pone.0010003-Kantarci1]. Two different polymorphisms in the promoter region of the matrix metalloproteinase 9 (MMP9) gene are associated with higher MMP9 expression and, in MS cases, were reported to lower the age-of-onset [@pone.0010003-Fiotti1], [@pone.0010003-MirowskaGuzel1] however this effect was not replicated in another study [@pone.0010003-Nelissen1]. Polymorphisms in the interleukin 4 gene and its receptor (IL4R) have also been shown to be associated not only with MS susceptibility [@pone.0010003-Kantarci2], [@pone.0010003-Mirel1], [@pone.0010003-Suppiah1] but also with a primary progressive course [@pone.0010003-Hackstein1].

More recently, a genome-wide phenotype-genotype study using gene-ontology techniques in patients with relapsing-remitting MS [@pone.0010003-Baranzini1] reported that the gene function categories "antigen processing and presentation" and "CNS development" were enriched in MS susceptibility whereas the categories of "axon guidance" and "glutamate signalling processes" were implicated in phenotypes of CNS damage, namely, T2 lesion load and brain volume.

The metrics in this study were chosen because they could be assessed in a large cohort of people with MS, and thus, it is possible that different measures could detect changes that could not be assessed here. SDT, for example, is a good screening tool for cognitive functional ability in MS, but if the various SNPs are associated with a regional deficit, or a specific functional change, then such an effect would not be detected in our study. Likewise, ICR is a validated measure of overall brain atrophy, but if potential modulating effects of the MS associated SNPs were brain-region specific, then the change might not be detected in this study. Additionally, it has been shown that aspects of MS disease phenotype are population-specific or stratify on the basis of ethnic origin. For example, in British and Scandinavian cohorts the HLA-DR2 allele imparts an earlier age of onset of disease [@pone.0010003-Masterman1], [@pone.0010003-Smestad1], [@pone.0010003-Hensiek1], [@pone.0010003-Weatherby1], [@pone.0010003-Celius1], whereas in a cohort from the USA no effect was observed [@pone.0010003-Barcellos1]. Beyond this, the potential interactions between disease associated SNPs and environmental factors may be different in cold climates than from tropical ones. As such, our results are particularly applicable to an MS population of Caucasian of predominantly British origin, resident in the temperate mid-latitudes (36°--43°S).

In this population, our study provided no evidence that MS severity or progression was altered by recently confirmed risk alleles in MS sufferers.
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